301 related articles for article (PubMed ID: 9764824)
1. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L
Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824
[TBL] [Abstract][Full Text] [Related]
2. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
[TBL] [Abstract][Full Text] [Related]
3. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
4. Role of TSG101 in uterine cervix cancer.
O'Boyle JD; Proctor ML; Fong KM; Lin WM; Miller DS; Muller CY
Gynecol Oncol; 1999 Dec; 75(3):401-5. PubMed ID: 10600297
[TBL] [Abstract][Full Text] [Related]
5. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
6. Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues.
Willeke F; Ridder R; Bork P; Klaes R; Mechtersheimer G; Schwarzbach M; Zimmer D; Kloor M; Lehnert T; Herfarth C; von Knebel Doeberitz M
Mol Carcinog; 1998 Dec; 23(4):195-200. PubMed ID: 9869447
[TBL] [Abstract][Full Text] [Related]
7. [Expression and its significance of TSG101 in lung cancer tissue and lung cancer cell lines.].
Cai C; Zhang D; Lu P; Gao Y; Chang J
Zhongguo Fei Ai Za Zhi; 2008 Apr; 11(2):172-7. PubMed ID: 20731896
[TBL] [Abstract][Full Text] [Related]
8. Absence of TSG101 transcript abnormalities in human cancers.
Trink B; Pai SI; Spunt SL; Raman V; Cairns P; Jen J; Gabrielson E; Sukumar S; Sidransky D
Oncogene; 1998 May; 16(21):2815-8. PubMed ID: 9652749
[TBL] [Abstract][Full Text] [Related]
9. Truncated TSG101 transcripts in human leukemia and lymphoma cell lines.
Hosokawa Y; Nagai E; Seto M
J Cancer Res Clin Oncol; 2000 Feb; 126(2):79-84. PubMed ID: 10664246
[TBL] [Abstract][Full Text] [Related]
10. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
12. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
13. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer.
Wu W; Kemp BL; Proctor ML; Gazdar AF; Minna JD; Hong WK; Mao L
Cancer Res; 1999 Apr; 59(8):1846-51. PubMed ID: 10213490
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
15. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
[TBL] [Abstract][Full Text] [Related]
16. The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer.
Sekine I; Sato M; Sunaga N; Toyooka S; Peyton M; Parsons R; Wang W; Gazdar AF; Minna JD
Oncogene; 2005 Apr; 24(16):2735-8. PubMed ID: 15735765
[TBL] [Abstract][Full Text] [Related]
17. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions.
Cairns P; Okami K; King P; Bonacum J; Ahrendt S; Wu L; Mao L; Jen J; Sidransky D
Cancer Res; 1997 Dec; 57(23):5356-9. PubMed ID: 9393760
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
[TBL] [Abstract][Full Text] [Related]
19. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer.
Okamoto A; Hussain SP; Hagiwara K; Spillare EA; Rusin MR; Demetrick DJ; Serrano M; Hannon GJ; Shiseki M; Zariwala M
Cancer Res; 1995 Apr; 55(7):1448-51. PubMed ID: 7882351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
